Financial Results, Upcoming Presentations, and Stock Price Movements - Research Report on Valeant Pharmaceuticals, St. Jude Medical, AstraZeneca, Stryker, and Smith & Nephew Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 6, 2013 NEW YORK, November 6, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Valeant Pharmaceuticals International Inc. (NYSE: VRX), St. Jude Medical, Inc. (NYSE: STJ), AstraZeneca plc (ADR) (NYSE: AZN), Stryker Corporation (NYSE: SYK) and Smith & Nephew plc (ADR) (NYSE: SNN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Valeant Pharmaceuticals International Inc. Research Report On October 31, 2013, Valeant Pharmaceuticals International Inc. (Valeant) reported its Q3 2013 financial results. The Company's total revenues increased 74.4% YoY to $1.5 billion during the quarter. Net loss attributable to Valeant was $973.2 million or $2.92 per diluted share in Q3 2013, compared to net income attributable to Valeant of $7.6 million or $0.02 per diluted share in Q3 2012. J. Michael Pearson, Chairman and CEO of Valeant, said, "Despite an unexpected early launch of a generic Retin-A Micro, significant headwinds this quarter from foreign exchange movements, and the demands of a major integration, we managed to beat expectations and position Valeant for a terrific fourth quarter and a strong 2014. I thank our team, both at Valeant and our new colleagues from Bausch + Lomb, for their commitment, diligence, and focus on execution. I am confident that our strategic focus on diversification, durable assets, key geographies, and low risk R&D will continue to benefit our shareholders as we look forward to continuing our track record of outperformance." The Full Research Report on Valeant Pharmaceuticals International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9fdd_VRX] -- St. Jude Medical, Inc. Research Report On November 1, 2013, St. Jude Medical, Inc. (St. Jude Medical) announced that it will present at the 2013 Credit Suisse Healthcare Conference on November 13, 2013, in Scottsdale, Arizona. St. Jude Medical reported that its Chairman, President, and CEO Dan Starks will address the conference at 8:00 a.m. PT. The Company also informed that the presentation will be webcast live at its website. The Full Research Report on St. Jude Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b338_STJ] -- AstraZeneca plc (ADR) Research Report On October 31, 2013, AstraZeneca plc (ADR) (AstraZeneca) reported its Q3 2013 financial results. The Company's revenue declined 6.5% YoY to $6.3 billion during the quarter. According to the Company, Q3 2013 revenue declined due to the ongoing impact from products with recent losses of exclusivity. Profit for the quarter stood at $1.2 billion and diluted earnings per ordinary share came in at $0.99, compared to profit of $1.5 billion and diluted earnings per ordinary share of $1.20 in Q3 2012. The Company stated that EPS in Q3 2013 included $0.18 per share benefit from the reversal of an intangible asset impairment related to the initiation of Phase III clinical trials of olaparib. The Full Research Report on AstraZeneca plc (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/09cc_AZN] -- Stryker Corporation Research Report On November 1, 2013, Stryker Corporation's stock (Stryker) rose 0.23%, ending the day at $74.03. Over the previous three trading sessions, shares of Stryker declined 0.67% compared to the S&P 500 which declined 0.58% during the same period. The Full Research Report on Stryker Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5b34_SYK] -- Smith & Nephew plc (ADR) Research Report On October 31, 2013, Smith & Nephew plc (ADR) (Smith & Nephew) reported its Q3 2013 financial results. The Company's revenue increased 7.9% YoY to $1.0 billion during the quarter. Attributable profit declined 7.6% YoY to $122 million and diluted EPS declined 8.2% YoY to $13.5 in Q3 2013. Commenting on the results, Olivier Bohuon, CEO of Smith & Nephew said, "Smith & Nephew had a strong third quarter, delivering 5% growth in revenue and 10% growth in trading profit on an underlying basis. Our global performance in Hip and Knee Implants improved following successful new product introductions and increased investment. We generated 20% revenue growth across our Emerging and International Markets. Advanced Wound Management significantly outperformed its segment with another excellent quarter from Healthpoint Biotherapeutics, which we have now rebranded as Smith & Nephew." He added, "Our markets remain tough, but through implementing our strategic priorities we are meeting these challenges, investing where we see the greatest opportunities for growth, and successfully reshaping the Group for long-term success." The Full Research Report on Smith & Nephew plc (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/eed3_SNN] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Financial Results, Upcoming Presentations, and Stock Price Movements - Research Report on Valeant Pharmaceuticals, St. Jude
Press spacebar to pause and continue. Press esc to stop.